Prostate cancer treatment outcomes, robotic techniques grabbing headlinesat this year's AUA
Over the next 5 days, urologists can expect to hear a great deal aboutprostate cancer treatment outcomes, robotic and minimally invasive surgicaltechniques, pelvic pain in both men and women, the obesity epidemic andits connection to prostate cancer, and advances in erectile dysfunctiontherapy. These are among the key areas of scientific research grabbing headlinesat this year's AUA annual meeting, said J. Brantley Thrasher, MD, chairof AUA's Public Media Committee.Dr. Thrasher briefed a small group of journalists yesterday on theseand other significant topics that make up part of the nearly 2,000 researchpapers being presented here.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.